Deutsche Bank AG Sells 6,053,828 Shares of Pfizer Inc. (NYSE:PFE)

Deutsche Bank AG trimmed its position in Pfizer Inc. (NYSE:PFE) by 18.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,392,761 shares of the biopharmaceutical company’s stock after selling 6,053,828 shares during the period. Deutsche Bank AG’s holdings in Pfizer were worth $700,200,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer in the fourth quarter valued at $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer in the fourth quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer in the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC bought a new stake in Pfizer during the fourth quarter worth $31,000. Finally, Curio Wealth LLC bought a new position in Pfizer during the 4th quarter valued at $32,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on PFE. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. UBS Group increased their price target on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Citigroup restated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Cantor Fitzgerald assumed coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $29.17.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Trading Down 0.5 %

Shares of PFE opened at $22.78 on Thursday. The stock has a market capitalization of $129.18 billion, a P/E ratio of 16.15, a PEG ratio of 0.64 and a beta of 0.58. The firm has a fifty day simple moving average of $24.15 and a two-hundred day simple moving average of $25.65. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s quarterly revenue was down 7.8% compared to the same quarter last year. During the same period last year, the company earned $0.82 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.55%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.